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Abstract—Manufacturing of medical devices is strictly con-
trolled by authorities, and manufacturers must conform to the
regulatory requirements of the region in which a medical device
is being marketed for use. In general, these requirements make
no difference between the physical device, embedded software
running inside a physical device. or software that constitutes the
device in itself. As a result, standalone software with intended
medical use is considered to be a medical device. Consequently, its
development must meet the same requirements as the physical
medical device manufacturing. This practice creates a unique
challenge for organizations developing medical software. In
this paper, we pinpoint a number of regulatory requirement
mismatches between physical medical devices and standalone
medical device software. The view is based on experiences from
industry, from the development of all-software medical devices
as well as from defining the manufacturing process so that it
meets the regulatory requirements.
Index Terms—Medical device software, medical software de-
velopment, medical device standards, regulatory requirements,
regulatory compliance
I. INTRODUCTION
The safety of health care, medical devices, and people
are among the main concerns of governments. Therefore,
manufacturing of medical devices is strictly controlled by
authorities, and manufacturers must conform to the regulatory
requirements of the region in which a medical device is
being marketed for use. Within the EU region, European
Commission runs a regulatory framework, and medical devices
are currently regulated by three directives, which will be
replaced by two new regulations. The new regulations will
fully apply after a transitional period. Based on the current
time limits, the transitional period lasts until May 2020 for
medical devices and until May 2022 for in vitro diagnostic
medical devices.
In the context of medical device software (MDSW), a
large number of products are currently being regulated by the
Council Directive 93/42/EEC on Medical Devices (MDD) [1]
and its latest amendment [2]. After the transitional period they
will be regulated by Regulation (EU) 2017/745 on medical
devices (MDR) [3]. Other directives and regulations may also
apply, depending on the type of software product.
Neither MDD nor MDR differentiates between the physical
device, embedded software running inside a physical device or
software that is the device itself [1], [3]. As a result, standalone
software with intended medical use is considered to be a
medical device, and its development must follow the same
directives, regulations, national laws, and technical standards
as the physical medical device manufacturing. This practice
creates a unique challenge for organizations developing medi-
cal software as it is evident that regulatory requirements were
created with physical devices in mind.
In this paper, we point out a number of regulatory re-
quirement mismatches between physical medical devices and
standalone medical device software. The challenges related
to these mismatches will become even more critical in the
near future when MDR is fully applied, and a large number
of existing medical software products will be up-classified
to higher classes. Consequently, as there will be hardly any
software-only products classified below Class IIa [4], the med-
ical software manufacturers must have a Quality Management
System (QMS) established and involve the Notified Body in
their certification process in order to be able to place the
products on the EU market.
The rest of this paper is structured as follows. In Section II,
we provide the background for the paper. In Section III, which
forms the core of the paper, we present some obvious mis-
matches between hardware-oriented regulatory requirements
and software. In Section IV, we give a brief discussion of our
observations. Finally, in Section V, we draw some conclusions.
II. BACKGROUND
In this section, we present an overview of EU regulation and
its different layers. Furthermore, the processes of CE marking
and placing on the EU market is discussed.
A. EU regulatory framework overview
The regulatory framework in the EU can be interpreted to
consist of several layers, including the following:





EU harmonized legislation includes legal acts of directives
and regulations. There is a significant difference between the
two: regulations will enter into force directly in all member
states, whereas directives define a specific set of objectives
that member states must fulfill, for example, with national
legislation. The latter approach leaves a certain amount of
leeway to member states, and it may result in variations in
national practices. However, it is also possible to supplement
EU regulations with national laws.
The EU Commission has noticed certain shortcomings in the
medical device directives [5] and, as discussed in Section I,
there is an on-going transitional period from current directives
to corresponding new regulations. Since the first entry into
force on April 2017, both regulations have been corrected
twice with a specific Corrigendum. It is worth to notice
that the 2nd Corrigendum for MDR included a surprisingly
significant change concerning to extended ”grace period” for
those devices that were classified as Class I devices by MDD
and that will be up-classified by MDR. Overall, the transition
process has demonstrated that changing the EU-wide legal
framework is a long and complicated process.
An essential feature of Union harmonization legislation
has been limiting the legislation to product-related essential
requirements that protect the health and safety of users and
stakeholders [6]. In the context of medical devices, essential
requirements ensure that medical devices are effective, safe to
use, and are able to achieve their intended use. However, a cer-
tain amount of technical details have been left to harmonized
standards.
European standards are technical specifications, adopted
first by a recognized standardization body – such as ISO
(https://www.iso.org/) and IEC (https://www.iec.ch/) – and
then by the European standardization organizations. Harmo-
nized standards are European standards adopted, by request
made by the EU Commission, for application of Union har-
monization legislation [6]. They usually include informative
annex that indicates the covered legal requirements and possi-
ble limitations of the coverage. Harmonized standards provide
a presumption of conformity with the essential requirements
they aim to cover. While the application of harmonized
standards is voluntary for the manufacturer, they are, in fact,
an effective tool to demonstrate conformity to regulatory
requirements.
The EU Commission has mechanisms to provide a range of
non-binding guideline documents in order to support uniform
application of the directives and regulations within the EU.
These guidance documents are usually developed in active
conjunction with the industry stakeholders. In the MDD con-
text, the most important sources are MEDDEV documents and
Consensus statements, whereas MDR related guidelines are
adopted by the Medical Device Coordination Group (MDCG)
with MDCG endorsed documents [7].
Finally, regulatory requirements with guidelines and har-
monized standards provide a general framework for medical
device development while leaving the responsibility to tailor
the details of the development process to the manufacturers.
B. CE marking for medical devices
A medical device product is considered to have been placed
on the market when it is made available for the first time on
the Union market [6]. Placing on the market is decisive point
as there is a legal consequence to comply with all applicable
Union legislation at that very moment. The CE marking is
the manufacturer’s claim that the product meets all relevant
regulatory requirements and the process must be completed
before the product can be placed on the market.
To simplify the process, the manufacturer must ensure that
[8]:
• The product’s intended use fulfills the definition of med-
ical device.
• The device risk classification has been done correctly
based on the intended use.
• The correct conformity assessment procedure has been
selected.
• All applicable regulatory requirements have been identi-
fied and thoroughly applied.
• All required technical documentation and the medical
device technical file are in place.
• The QMS has been established (if required by the con-
formity assessment procedure).
• The Notified Body has been involved in the assessment
(if required by the device risk classification).
• The new MDR requirements related to unique device
identifiers (UDI) have been fulfilled.
• A declaration of conformity has been signed.
• CE marking has been applied to the device.
• Registration to the national competent authority or, in the
case of MDR, to EUDAMED database, has been done.
As already mentioned, under MDR almost all MDSW prod-
ucts will require Notified Body involvement in the certification
process. Notified Bodies are third party conformity assessment
bodies designated by their national competent authority of a
member state and they carry out the procedures for conformity
assessment within the meaning of applicable Union harmo-
nization legislation [6].
III. MISMATCH BETWEEN HARDWARE AND SOFTWARE
In this section, we point out a number of regulatory re-
quirement mismatches between physical medical devices and
standalone medical device software.
A. Design Change Approval Process as a barrier to Contin-
uous Deployment
Continuous maintenance [9], or the tendency to keep soft-
ware alive with constant modifications, is nowadays well built
into software development practices. DevOps [10], Continuous
Deployment [11] and Continuous Software Engineering [12]
are all build on the opportunity to fix bugs, add missing
features, and test new, innovative ideas with running software,
with real end-users [13]. However, this approach is clearly
in conflict with regulatory framework and Notified Body
practices.
MDD wording related to design change notifications and
approvals differs slightly between the different product specific
conformity assessment annexes. In the context of software-
only medical device, Annex II is used. Annex II, section 4.4
outlines: ”Changes to the approved design must receive further
approval from the notified body which issued the EC design-
examination certificate wherever the changes could affect
conformity with the essential requirements of the Directive
or with the conditions prescribed for use of the product. The
applicant shall inform the notified body which issued the EC
design-examination certificate of any such changes made to the
approved design. This additional approval must take the form
of a supplement to the EC design-examination certificate” [1].
Notified Body Operations Group’s (NBOG) Best Practice
Guide Guidance for manufacturers and Notified Bodies on
reporting of Design Changes and Changes of the Quality
System [14] explains the basic principles by which medical
device design changes are evaluated by Notified Bodies. In
general, NBOG’s Best Practice Guides provide guidance on
specific aspects related to Notified Body operations and are
therefore mainly targeted for Notified Bodies. NBOG BPG
2014-3 differs from this convention as it is clearly targeted also
for medical device manufacturers. While NBOG’s guidance
documents are not legally binding, they are largely adopted
by Notified Bodies and organizations responsible for Notified
Body designation and control, in order to harmonize and im-
prove the performance of Notified Bodies. As a result, medical
device manufacturers are, in practice, expected to follow the
principles and requirements outlined in these guidelines in
their interaction with their assigned Notified Body.
NBOG BPG 2014-3 requires manufacturer to have a doc-
umented change assessment process with appropriate roles
and responsibilities [14]. Furthermore, list of more detailed
requirements related to the process is given. For example,
the manufacturer shall define change implementation plan in
order to monitor the change stages and to ensure compliance
to regulatory requirements, update the technical documenta-
tion, perform verification and validation activities, classify the
change as substantial or non-substantial, and document the
decision and timing of the change implementation.
NBOG BPG 2014-3 also addresses the criteria for deciding
if the change is substantial or non-substantial. It is obvious that
every change that may affect the conformity with the essential
requirements should be treated as substantial. The same applies
to changes that affect to product’s intended use, risk profile,
intended user base, or clinical performance. Changes related
to software are specifically addressed in chapter 5.4 and
various examples are given. It should be noted that the list
of substantial change types is considerably longer than its
opposite. To elaborate, the list of non-substantial software
changes includes only logic error corrections (that do not pose
a safety risk), non-therapeutic and/or non-diagnostic functions
(such as printing, faxing, and additional language support),
UI appearance changes (with no more than negligible risk of
impacting the diagnosis or therapy delivered), and changes to
disable a feature that does not interact with other features.
It is recommended for manufacturers to contact their Notified
Body in any questions related to change classification in order
to get mutual understanding.
According to NBOG BPG 2014-3 [14], Notified Body must
process the change reports with the appropriate actions, for
example documenting the assessment related to the product
or complete re-assessment of the design documentation of the
medical device file, updating the EC certificate if needed, re-
viewing and updating the contract if needed, and documenting
related items that need to be addressed in the next quality
management system audit.
A similar design change approval process can be found from
MDR, Annex IX 4.10 [3]: ”Changes to the approved device
shall require approval from the notified body which issued
the EU technical documentation assessment certificate where
such changes could affect the safety and performance of the
device or the conditions prescribed for use of the device”. As
there is currently no MDR specific guidance addressing this
issue, it is very likely that the Notified Bodies will continue
operating according to their current processes that are based
on the guidance given by NBOG BPG 2014-3.
It is evident that a process like the one described above is
cumbersome for both the manufacturers and Notified Bodies.
From the viewpoint of continuous maintenance and agile
software development, it can be seen as a huge barrier. Small
bug fixes and error corrections can be addressed according
to modern software development practices whereas any new
safety or clinical performance related features must be ap-
proved by regulatory authorities. Therefore, the availability of
Notified Body services and resources can be seen as a critical
aspect in order to ensure that continuous maintenance activities
can be performed in timely manner. Unfortunately, based on
authors’ experience on the matter, this kind of service level is
not often available.
B. Single-fault condition
The term single fault condition (SFC) can be found from the
MDD [1]. The essential requirements in Annex I are grouped
under different subheading, and the term appears a total of
three times under the following subheadings:
1) Construction and environmental properties,
2) Requirements for medical devices connected to or
equipped with an energy source, and
3) Protection against electrical risks.
As a result of the wording of the directive, the current inter-
pretation of regulatory authorities is that the SFC is relevant
concept exclusively in the context of active physical medical
devices. This conclusion is supported by the available guidance
documents and IEC 60601 -standard series, where the term is
being addressed in the electrical safety context.
However, this interpretation is not valid in the context of the
MDR [3] - on the contrary, the term SFC is explicitly con-
nected to software-only device in the Annex I, General safety
and performance requirements, in sub-section 17.1: ”Devices
that incorporate electronic programmable systems, including
software, or software that are devices in themselves, shall be
designed to ensure repeatability, reliability and performance
in line with their intended use. In the event of a single fault
condition, appropriate means shall be adopted to eliminate or
reduce as far as possible consequent risks or impairment of
performance”.
From this point of view, there is a clear deviation between
the MDD and MDR. This creates the problem of the definition
of the term in the software context as the current regulation
and guidance is related to physical electrical devices. In
software context, there is no generally accepted or generally
used definition for the term. Currently, undoubtedly the most
important source for the definition is harmonized standard
IEC/EN 60601-1 Medical electrical equipment - Part 1: Gen-
eral requirements for basic safety and essential performance,
where the term is defined as: ”condition in which a single
means for reducing a RISK is defective or a single abnormal
condition is present”. The standard also lists few concrete
examples related to electrical safety. However, the definition
could be used as a first stage when elaborating the exact
meaning in the software context.
C. Public Cloud Computing Platforms
During the last decade, public cloud computing platforms
have gained popularity among software development compa-
nies. Major public cloud suppliers like Amazon Web Services
(AWS), Microsoft Azure and Google Cloud offer services
that consist of hundreds of ready-made software components.
While relaying heavily to cloud computing solutions can still
be seen as an innovative decision, cloud computing is heading
towards mainstream adoption [15] with massive deployments
in various application domains [16]. However, there are some
significant challenges when adopting public 3rd party cloud
computing solutions to medical device software development.
International Medical Device Regulators Forum’s (IMDRF)
technical document Software as a Medical Device (SaMD):
Clinical Evaluation [17] describes the process of how stan-
dalone medical software should be clinically evaluated. The
technical document is wildly adopted by Notified Bodies and
used in medical software conformance assessments. Accord-
ing to IMDRF, SaMD clinical evaluation is a planned and
systematic process to collect, generate, analyze and assess
continuously the clinical data in order to create clinical evi-
dence to prove the clinical association and performance of the
SaMD as intended by the manufacturer. The clinical evaluation
process consists of three steps, (i) Valid clinical association,
(ii) Analytical validation, and (iii) Clinical validation. In more
detail, the analytical validation step includes technical valida-
tion. Technical validation should provide objective evidence
that the software was correctly constructed and that it cor-
rectly and reliably processes data accurately and reproducible.
This evidence is usually generated and collected during the
verification and validation phase of the software development
process. In practice, these technical validation requirements
expose the cloud platform to a more detailed analysis.
The complexity level of the public cloud computing environ-
ments creates challenges for the demonstration of conformity.
The manufacturer must be able to provide the documentation
as required by the regulatory requirements related to ade-
quate performance, risk management and cybersecurity – the
medical device technical documentation should contain clear
description of responsibilities between the manufacturer and
the cloud platform provider. Furthermore, when processing
sensitive health data, the storage requirements related to data
location and retention times must be taken into account.
The cloud-native application (CNA) design seems to corre-
late highly with cloud-native architecture and design patterns
[18]. These design guidelines are given by the platform
provider when using a specific cloud computing environment.
In practice, this leads to the heavy use of the platform’s ready-
made components as a part of the medical device software. In
fact, in CNA the self-developed part of the software might
be significantly smaller than the functionality provided by the
existing cloud components. It is undoubtedly a challenge for
the manufacturer to create appropriate technical documentation
for these 3rd party components and ensure that they remain
unchanged after MDSW has been validated. Furthermore,
according to MDR Annex I, 17.2 [3], the MDSW must be
developed and manufactured taking into account the principles
of the development life cycle – it is highly unlikely that the
manufacturer has much control over cloud computing platform
supplier’s development process.
If the manufacturer addresses cloud computing platform and
its existing components as software of unknown provenance
(SOUP) items according to standard IEC/EN 62304 [19], the
specific SOUP requirements of the standard must be fully
applied and adequate evidence documented. For example,
the manufacturer must specify functional and performance
requirements of SOUP items (cl. 5.3.3), verify that the MDSW
architecture supports operation of SOUP items (cl. 5.3.6),
create the process to evaluate and implement upgrades and
fixes of SOUP items (cl. 6.1), consider potential hazardous
situations arising from SOUP item failures (cl. 7.1.2), evaluate
published SOUP anomaly lists (cl. 7.1.3), analyze the impact
of changes to SOUP with respect to safety (cl. 7.4.1) and
on existing risk control measures (cl. 7.4.2), and identify and
document all SOUP configuration items (cl. 8.1.2). It is evident
that this level of scrutiny in documentation requirements is
a big challenge when considering 3rd party cloud computing
components.
D. Artificial Intelligence and Machine Learning under the
regulatory framework
With Artificial Intelligence (AI) and Machine Learning
(ML) solutions, it is possible to design systems that utilize
existing health care data to create new insight for the benefit
of the patients. Furthermore, with the recent advances in AI
and ML, systems that improve as they perform their critical
operations are becoming a reality. For instance, systems that
interpret images, recognize speech, and so on can learn on
the fly as more and more input data is made available. In
contrast, hardware that would improve itself on the fly is still
in the laboratories at best, and not ready for prime use. In
regulatory actions, there are little possibilities for such silent
improvement. In contrast, the regulation aims at keeping the
system as it is, with human-validated features [3], [20].
The main difference between the AI/ML system and tra-
ditional software product lies, in particular, in the former’s
ability to adapt and optimize operations in real-time. However,
it is possible to design ML application in a way that the
system is being trained during the development phase, and the
ability to improve is disabled in real-world use. Based on the
authors’ experience on the matter, this approach is currently
indeed promoted amongst EU regulators. As discussed earlier
in this Section, all design changes that affect product’s clinical
performance should be treated as substantial and therefore
obtain formal approval according to design change approval
process. Clearly, this approach to lock systems self-learning
severely limits the efficiency of the ML technology.
While MDR seeks to remedy MDD shortcomings and, as a
result, explicitly addresses certain new concepts regarding sci-
entific innovations and emerging manufacturing technologies,
AI and ML are not among them. Evidently this is a severe
shortcoming in the revised legislation. Against this back-
ground, it is surprising to see the theme ”Artificial Intelligence
under MDR/IVDR framework” addressed in MDCG’s ongoing
guidance development list under Section 7, New Technologies
[21]. Guidance on this aspect is highly anticipated by industry
stakeholders as there are some significant concerns related to
the interpretation of the issue under the MDR. For example,
it might be possible to interpret the classification Rule 22
from Annex VIII, Chapter III [3] as applicable to AI/ML-
based systems, and, as a result, the risk classification of these
systems would raise to Class III. Obviously, such an important
principle should be clear for the manufacturer right from the
start of the product innovation process in order to ensure lean
market entry for AI/ML-based system.
E. Quality Management System Implementation
ISO 13485:2016 Medical devices - Quality management
systems - Requirements for regulatory purposes [22] is a
widely acknowledged standard that defines requirements for
the Quality Management System (QMS) for the design and
manufacturing processes of medical devices. As it is a harmo-
nized standard, it provides a presumption of conformity with
the Essential Requirements [6], which are, in this context, the
requirements outlined in MDD Annex II.
The QMS processes defined in ISO 13485:2016 are well
suited for the organizations performing hardware product
manufacturing. However, this is not the case when developing
software products where the manufacturing process is more
abstract by nature. For example, ISO 13485:2016 requires
separate process for transferring the design and development
outputs to manufacturing in chapter 7.3.8. In the context
of software development, this requirement can be relatively
artificial [23] as the design and development output is finished
software artifact which does not need to be further processed
or manufactured.
Furthermore, ISO 13485:2016 states that infrastructure and
work environment must be designed to support the design,
development, manufacturing and final inspection of the med-
ical device product according to the product and regula-
tory requirements. When considering physical manufacturing
environment, it is not difficult to understand how lack of
infrastructure and work environment control can have an
adverse effect to the product quality and, furthermore, to the
safety of the product. In contrast, similar physical requirements
are generally not applicable in software development context
where ordinary office environment is suitable for design and
development of the software-only device.
In contrast to the 2003 revision of the standard, the scope
of the 2016 revision has been expanded to be more suitable
for any type of organization participating in any activity of
the medical device life-cycle. For example, non-applicability
option has been extended as not all organizations are expected
to perform the full scope of activities addressed in the standard.
ISO 13485:2016 states: ”If any requirement in Clauses 6, 7
or 8 of this International Standard is not applicable due to
the activities undertaken by the organization or the nature of
the medical device for which the quality management system
is applied, the organization does not need to include such
a requirement in its quality management system. For any
clause that is determined to be not applicable, the organization
records the justification as described in 4.2.2.” [22]. However,
we could not identify any documented guidance to harmonize
regulators’ practices related to non-applicability option assess-
ments as [23] does not directly address this matter.
IV. DISCUSSION
Reconsidering regulatory approaches in MDSW develop-
ment is needed to ensure compliance with new EU medical
device regulations. Furthermore, special attention is required
in order to use new software development approaches with
medical devices in full [24], [25]. However, even with the
present setup, it is possible to use advanced toolchains, as-
suming that they have taken regulatory aspects into account
[26]. Nonetheless, the technical ability to use continuous de-
ployment practices, while simultaneously creating regulatory
evidence, can be interpreted to be only partial optimization.
As almost all MDSW products will require the Notified
Body involvement in the certification process under the new
regulations, the co-operational processes between the medical
device manufacturer and the Notified Body play a very central
role. Compared to current design change approval procedure,
a more streamlined practice is undoubtedly needed to allow
continuous software releases.
MDR brings the term single fault condition explicitly to the
software context. Considering the SFC, the definition from the
IEC/EN 60601-1, as discussed in Section III, could be used
to highlight the underlying concept of single fault safe: the
product is considered to be safe even if one safety-related
requirement or feature fails. In other words, the device’s
overall risk level needs to remain acceptable even if one feature
that involves patient risk, or one risk mitigation fails. In the
software and IEC/EN 62304 context, risk control measures
for hardware failures and potential software defects must
be included to software requirements [19]. As a result, all
software requirements that are in some way connected to
unacceptable risk - either involving or mitigating one - are
affected by SFC requirement. With this approach, useful and
feasible meaning for the term SFC in the software context
could be defined, yet the definition would be useful only if
adopted by regulatory authorities.
A critical aspect of using a public cloud computing platform
as a technology selection for MDSW is to ensure compliance
with regulatory requirements. Major cloud operators are mo-
tivated to serve a wide range of different domains, and their
platforms are already used by numerous mission-critical sec-
tors, e.g., financial operators. The cloud operators are willing
to provide compliant documentation about their services and
components, and security and data protection issues are com-
monly addressed by their infrastructure architecture implicitly.
The shared responsibility model of the cloud operator must
be well-understood by the manufacturer and appropriately
addressed both in product’s technical documentation and in the
quality management system. For the QMS, the manufacturer
should pay a particular focus to cloud governance, configu-
ration management, access control, data encryption, logging
and monitoring, incident response, and disaster recovery. The
manufacturer must validate the MDSW product built to the
cloud environment as usual and the platform operator ensures
that their version controlled components and virtual images
conform to pre-defined interface specifications and service
level agreements.
When considering the complexity of the MDSW product’s
regulatory compliance in the cloud environment, it is evident
that cross-functional skill-set is needed to provide requisite
regulatory evidence. Skillfully designed cloud application
architecture could provide specific additional benefits com-
pared to traditional on-premise environments, such as better
operational resilience with isolated infrastructure, real-time
verification and monitoring, and audit logging. Bearing the
mentioned complexities and potential benefits in mind, smaller
manufacturers could benefit from the cooperation with each
other or with certain suppliers with the ability to deliver a
high-quality cloud solutions.
It is somewhat surprising that MDR is not explicitly address-
ing AI/ML-driven systems. While an increasing amount of new
medical device innovations are based on AI/ML systems, the
industry stakeholders remain uncertain on how these products
will be assessed by the regulatory authorities. Concerning
to this issue, U.S. Food and Drug Administration’s (FDA)
processes are not much more advanced [27] as currently
cleared or approved systems typically include only ”locked”
algorithms and algorithm changes would likely require FDA
premarket review. However, on April 2, 2019, FDA published
a discussion paper [27] that describes a potential approach to
review AI/ML-driven systems. The proposed approach would
allow the product to improve in iterative manner while, at the
same time, ensure the safety of the patient by enabling real-
world performance monitoring. The approach would require
manufacturer’s commitment for transparency as FDA would
expect to get periodic updated on what product changes were
implemented.
In practice, the manufacturers of MDSW must implement a
quality management system in compliance with ISO 13485
based on the applicable conformity assessment procedures.
In ISO 13485, there are certain elements and procedure
requirements that are not well-suited for the manufacturers
of software-only devices. In the lack of authoritative guidance
on the use of the non-applicability option, the practices may
vary amongst assessment bodies and such a variation would
jeopardize the equal treatment of manufacturers.
V. CONCLUSIONS
In this paper, we have discussed a few essential EU reg-
ulatory requirement mismatches between a physical medical
device and standalone software product with intended medical
use. The current EU regulatory framework was examined for
requirements that do not align well in a software-only context.
Special consideration was given to conformity assessment
process involving the Notified Body and their assessment
practices for the reason of their importance under the new
regulations.
First, we reviewed the change assessment process related
to those MDSW products, whose certification process must
involve Notified Body assessment under the current directives.
We would highly welcome a more streamlined process under
the new regulations as the number of MDSW products affected
increases substantially, and the current approach is an obstacle
to the efficient use of continuous deployment methods. Second,
the term single fault condition was considered in the software
context. There is a degree of uncertainty around the term as
it remains unexplained by regulatory authorities. However, we
proposed a baseline from which the term could be defined.
Third, the compliance challenges related to public cloud
computing platforms were addressed. The complexity of the
cloud environment creates challenges for the manufacturer
to collect appropriate regulatory evidence. For this reason,
a well-skilled workforce is required. Fourth, the concepts
of artificial intelligence and machine learning were reviewed
from the viewpoint of regulatory requirements. The identified
challenges are related to validation and design change approval
processes. MDCG has ongoing guidance development in this
field, yet the planned endorsement schedule is open. Last,
ISO 13485 standard was researched for it suitability for the
manufacturer of software-only devices. Although the standard
includes a non-applicability option, the interpretation might
vary among the stakeholders.
Given the current maturity level of the new EU regu-
latory framework, the future work will include monitoring
and analyzing the evolving legislation harmonization work.
It is particularly important to gather the new requirements
and insight from the MDSW related standards and guide-
lines yet unpublished. Creating a more streamlined design
change approval process would require close co-operation with
the regulatory authorities, standardization bodies, and other
stakeholders. Although creating such an optimized process
may be challenging to do, we believe it would benefit the
entire medical device domain. Also, it could be possible to
achieve significant clinical benefits if the potential of AI/ML-
driven application could be fully utilized in adaptive yet safety
ensuring mode. Manufacturers willing to use public cloud
computing platforms in their medical device solutions could
reduce their regulatory burden and benefit from ready-made,
distributed solutions that take into account the regulatory
requirements.
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